A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC

NCT04990258 · clinicaltrials.gov ↗

UNKNOWN

Status

444

Enrollment

OTHER

Sponsor class

Conditions

Inflammatory Bowel Diseases

Interventions

DRUG: Subcutaneous infliximab CT-P13 Remsima®SC

Sponsor

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Collaborators

[object Object]